SAGE Therapeutics (SAGE) Stock: Halted On FDA AC Review!

0

Sage Therapeutics SAGE Stock NewsSAGE Therapeutics Inc (NASDAQ: SAGE) is halted in today’s trading session, and after the halt, we’re likely to see either big gains or big declines. That’s because the halt comes as the FDA and its Advisory Committees meet to discuss a New Drug Application from the company. Should the discussions go well, the stock could fly. Should the discussions turn out negative, the stock could tank. Today, we’ll talk about:

  • The Advisory Committee meeting;
  • why this is so important for SAGE; and
  • what we’ll be watching for with regard to the stock ahead.

SAGE Halted For FDA Advisory Committee Meeting

As mentioned above, Sage Therapeutics is halted early on in today’s trading session as the company meets with the FDA. Today, the FDA will be meeting with the company as well as the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Comittee.

During the meeting, the parties will discuss the recent New Drug Application submitted by SAGE. The application is currently under review for ZULRESSO, which is an injection for the treatment of postpartum depression.




Why This Is So Important

At the end of the day, Advisory Committees are hand selected by members of the FDA. These committees provide their opinions on whether or not a drug should be approved for marketing in the United States. While their opinions are not binding, it is very uncommon for the FDA to send a decision down the line with regard to approval that goes against the advise of these committees. So, if all goes well with the meeting, SAGE will likely rocket as investors see a strong chance of approval ahead. However, if the meeting doesn’t go well, the stock will likely tank as investors show concern for the outcome of the New Drug Application.

What To Watch For

One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Sage Therapeutics, the news will move the stock as soon as the halt is lifted. The meeting is expected to run from 8:00 AM this morning until 5:00 PM tonight. Keep an eye on the documents that are released after the meeting for hints as to where the stock is headed next.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on SAGE. In particular, we’re interested in following the Advisory Committee meeting and the outcome of the meeting as it will likely prove to be a catalystic event. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Previous articleAlkermes (ALKS) Stock: Tumbling On FDA News
Next articleInpixon (INPX) Stock: Positive News Dampens RS Declines
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at CNAFinanceHelp@gmail.com Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.

LEAVE A REPLY

Please enter your comment!
Please enter your name here